Valeant Files Quarterly Report, Avoiding Default on Debt

Valeant Pharmaceuticals International Inc. filed its first-quarter report with U.S. regulators on Tuesday, avoiding a default on its debt and beating a self-imposed deadline.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.